IL221744A - Use of combination of compounds for preparation of a medicament for treating parkinson's disease - Google Patents

Use of combination of compounds for preparation of a medicament for treating parkinson's disease

Info

Publication number
IL221744A
IL221744A IL221744A IL22174412A IL221744A IL 221744 A IL221744 A IL 221744A IL 221744 A IL221744 A IL 221744A IL 22174412 A IL22174412 A IL 22174412A IL 221744 A IL221744 A IL 221744A
Authority
IL
Israel
Prior art keywords
drug
disease
prepare
compounds
combination
Prior art date
Application number
IL221744A
Other languages
English (en)
Hebrew (he)
Original Assignee
Orion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Corp filed Critical Orion Corp
Publication of IL221744A publication Critical patent/IL221744A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL221744A 2010-03-04 2012-09-02 Use of combination of compounds for preparation of a medicament for treating parkinson's disease IL221744A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US31039810P 2010-03-04 2010-03-04
US41282110P 2010-11-12 2010-11-12
US201161438416P 2011-02-01 2011-02-01
PCT/FI2011/000013 WO2011107653A2 (en) 2010-03-04 2011-03-03 Method for treating parkinson's disease

Publications (1)

Publication Number Publication Date
IL221744A true IL221744A (en) 2016-11-30

Family

ID=44065577

Family Applications (1)

Application Number Title Priority Date Filing Date
IL221744A IL221744A (en) 2010-03-04 2012-09-02 Use of combination of compounds for preparation of a medicament for treating parkinson's disease

Country Status (14)

Country Link
US (4) US20130137729A1 (OSRAM)
EP (1) EP2542220B1 (OSRAM)
JP (2) JP5774610B2 (OSRAM)
KR (1) KR101868326B1 (OSRAM)
CN (1) CN102781424B (OSRAM)
AU (1) AU2011222856B2 (OSRAM)
BR (1) BR112012018256A8 (OSRAM)
CA (1) CA2784819C (OSRAM)
EA (1) EA026419B1 (OSRAM)
ES (1) ES2614179T3 (OSRAM)
IL (1) IL221744A (OSRAM)
MX (1) MX336187B (OSRAM)
WO (1) WO2011107653A2 (OSRAM)
ZA (1) ZA201205836B (OSRAM)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2545178T3 (es) 2005-07-26 2015-09-09 Bial-Portela & Ca, S.A. Derivados de nitrocatecol como inhibidores de la COMT
EP1845097A1 (en) 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazole derivatives as COMT inhibitors
DK2481410T3 (en) 2007-01-31 2016-10-24 Bial - Portela & Ca S A Nitrocatecholderivater as COMT inhibitors administered in a specific dosage regimen
CL2009000628A1 (es) 2008-03-17 2010-04-09 Bial Portela & Companhia S A Forma cristalina de 5-[3-(2,5-dicloro-4,6-dimetil-1-oxi-piridin-3-il)-[1,2,4]oxadiazol-5-il]-3-nitrobenceno-1,2-diol, composicion farmaceutica que la comprende, proceso para obtenerla y su uso para tratar trastornos del animo, enfermedad de parkinson y trastornos parkinsonianos, alteraciones gastrointestinales, entre otros.
KR20210009441A (ko) 2009-04-01 2021-01-26 바이알 - 포르텔라 앤드 씨에이 에스에이 니트로카테콜 유도체를 포함하는 제약 제제 및 그의 제조 방법
CN102781424B (zh) * 2010-03-04 2016-03-30 奥赖恩公司 左旋多巴、卡比多巴和恩他卡朋用于治疗帕金森病的应用
US20140045900A1 (en) * 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
WO2012147099A1 (en) * 2011-04-25 2012-11-01 Suven Nishtaa Pharma Pvt. Ltd. Pharmaceutical compositions of levodopa, carbidopa and entacapone
EP2791134B1 (en) 2011-12-13 2019-09-25 BIAL - Portela & Cª S.A. Chemical compound useful as intermediate for preparing a catechol-o-methyltransferase inhibitor
EP2934540B1 (en) * 2012-12-24 2023-08-02 Neurogastrx, Inc. Methods for treating gi tract disorders
US9642810B2 (en) 2013-03-15 2017-05-09 Mylan Inc. Formulation containing carbidopa, levodopa, and entacapone
EP2799065A1 (en) * 2013-04-30 2014-11-05 Deva Holding Anonim Sirketi Levodopa carbidopa entacapone pharmaceutical formulations
WO2015200369A1 (en) 2014-06-24 2015-12-30 Neurogastrx, Inc. Prodrugs of metopimazine
WO2016083863A1 (en) 2014-11-28 2016-06-02 Bial - Portela & Ca, S.A. Medicaments for slowing parkinson's disease
KR20180041234A (ko) * 2015-08-27 2018-04-23 프렉스톤 테라퓨틱스 에스에이 레보도파로 유발된 이상운동증 치료용 뇌 침투성 크로몬 옥심 유도체
NZ768098A (en) 2018-03-23 2025-12-19 Lobsor Pharmaceuticals Ab Continuous administration of pharmaceutical composition for treatment of neurodegenerative disorders
TW202031265A (zh) 2018-11-15 2020-09-01 美商艾伯維有限公司 用於皮下投藥之醫藥調配物
CN112741808B (zh) * 2019-10-29 2024-02-06 南京济群医药科技股份有限公司 一种提高含盐酸苄丝肼口服固体组合物稳定性的方法
US10836757B1 (en) 2020-04-02 2020-11-17 Neurogastrx, Inc. Polymorphic forms of metopimazine
US20230181493A1 (en) * 2020-04-10 2023-06-15 Senda Biosciences, Inc. Biomarkers related to parkinson's disease and methods of using the same
EP4223288B1 (en) 2022-02-07 2024-03-06 Berlirem GmbH Novel kit of pharmaceutical preparations for the treatment of parkinson's disease
GB202212082D0 (en) * 2022-08-18 2022-10-05 Bial Portela & Ca Sa Treatment regimens for parkinson's disease
KR102903389B1 (ko) 2022-11-30 2025-12-23 주식회사한국파마 신경퇴행성 질환 예방 또는 치료용 필름코팅정제

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3462536A (en) 1960-07-22 1969-08-19 Merck & Co Inc Method of inhibiting decarboxylase
DK175069B1 (da) 1986-03-11 2004-05-24 Hoffmann La Roche Pyrocatecholderivater
US5236952A (en) 1986-03-11 1993-08-17 Hoffmann-La Roche Inc. Catechol derivatives
JPH02138A (ja) 1987-09-18 1990-01-05 Banyu Pharmaceut Co Ltd Ｌ‐ドーパ誘導体
GB2238047B (en) 1989-11-03 1993-02-10 Orion Yhtymae Oy Stable polymorphic form of (e)-n,n-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide and the process for its preparation
US5607969A (en) 1992-12-24 1997-03-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem L-DOPA ethyl ester to treat Parkinson's disease
GB2344819A (en) 1998-12-18 2000-06-21 Portela & Ca Sa 2-Phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones
FI109453B (fi) 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
US20040166159A1 (en) * 2002-05-29 2004-08-26 Chien-Hsuan Han Pharmaceutical dosage forms having immediate and controlled release properties that contain an aromatic amino acid decarboxylase inhibitor and levodopa
US20060013875A1 (en) * 2002-05-29 2006-01-19 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
AU2003293423A1 (en) 2002-12-06 2004-06-30 Xenoport, Inc. Carbidopa prodrugs and uses thereof
WO2005063696A2 (de) 2003-12-31 2005-07-14 Cilag Ag Neue kristalline formen von entacapone und deren herstellung
CN101023056B (zh) 2004-06-04 2011-05-25 克塞诺波特公司 左旋多巴前药、和组合物及其应用
WO2006037061A2 (en) * 2004-09-28 2006-04-06 Farouk Karoum Compositions and methods of using d-dopa to treat parkinson's disease
WO2006131591A2 (en) * 2005-06-08 2006-12-14 Orion Corporation An entacapone-containing oral dosage form
MY148644A (en) 2005-07-18 2013-05-15 Orion Corp New pharmaceutical compounds
ES2545178T3 (es) 2005-07-26 2015-09-09 Bial-Portela & Ca, S.A. Derivados de nitrocatecol como inhibidores de la COMT
WO2007067495A2 (en) 2005-12-05 2007-06-14 Xenoport, Inc. Levodopa prodrug mesylate, compositions thereof, and uses thereof
EP2104424A4 (en) 2006-10-30 2011-06-15 Wockhardt Research Center PHARMACEUTICAL COMPOSITIONS COMPRISING ENTACAPONE, LEVODOPA, AND CARBIDOPA
MX2010009043A (es) 2008-02-28 2010-10-25 Bial Portela & Ca Sa Composicion farmaceutica para farmacos poco solubles.
CA2734972C (en) * 2008-08-22 2017-03-28 Wockhardt Research Centre An extended release pharmaceutical composition of entacapone or salts thereof
KR20110046555A (ko) * 2008-08-22 2011-05-04 욱크하르트 리서치 센터 레보도파, 카비도파 및 엔타카폰 또는 이의 염을 포함하는 단일 단위 경구 투여 약학 조성물
TR200806646A2 (tr) * 2008-09-03 2009-06-22 Dr. F. Fri̇k İlaç San. Ve Ti̇c. A.Ş. Entakapon, levodopa ve karbidoba içeren farmasötik kombinasyonlar
EP2233131A1 (en) 2009-03-23 2010-09-29 Laboratorios Lesvi, S.L. Pharmaceutical composition containing levodopa, entacapone and carbidopa
CN102781424B (zh) * 2010-03-04 2016-03-30 奥赖恩公司 左旋多巴、卡比多巴和恩他卡朋用于治疗帕金森病的应用
JP5551001B2 (ja) 2010-06-22 2014-07-16 株式会社Ｐｆｕ 摩擦係数推定装置および摩擦係数推定方法
JP2015006373A (ja) * 2014-07-14 2015-01-15 株式会社大都技研 遊技台

Also Published As

Publication number Publication date
HK1177896A1 (zh) 2013-08-30
US11771675B2 (en) 2023-10-03
WO2011107653A3 (en) 2011-11-03
WO2011107653A8 (en) 2012-08-02
EP2542220A2 (en) 2013-01-09
CA2784819C (en) 2018-02-13
EP2542220B1 (en) 2016-11-02
US20130137729A1 (en) 2013-05-30
ZA201205836B (en) 2014-01-29
ES2614179T3 (es) 2017-05-30
WO2011107653A2 (en) 2011-09-09
US20150150839A1 (en) 2015-06-04
US20210085635A1 (en) 2021-03-25
AU2011222856A1 (en) 2012-07-26
MX2012010161A (es) 2012-10-03
US20240050394A1 (en) 2024-02-15
JP2013521263A (ja) 2013-06-10
JP2015180644A (ja) 2015-10-15
AU2011222856B2 (en) 2015-10-15
US10857120B2 (en) 2020-12-08
KR101868326B1 (ko) 2018-06-19
EA201290865A1 (ru) 2013-02-28
MX336187B (es) 2016-01-07
BR112012018256A8 (pt) 2017-12-19
US12521363B2 (en) 2026-01-13
BR112012018256A2 (OSRAM) 2011-09-09
CN102781424A (zh) 2012-11-14
EA026419B1 (ru) 2017-04-28
CA2784819A1 (en) 2011-09-09
KR20130006638A (ko) 2013-01-17
CN102781424B (zh) 2016-03-30
JP5774610B2 (ja) 2015-09-09

Similar Documents

Publication Publication Date Title
IL221744A (en) Use of combination of compounds for preparation of a medicament for treating parkinson's disease
IL269511A (en) New therapeutic approaches for treating parkinson's disease
BR112012004166A8 (pt) colocação otimizada de cânula para aplicação de agentes terapêuticos ao cérebro
SMT201600281B (it) Trattamento di disturbi correlati a bdnf usando laquinimod
BRPI1012116A2 (pt) composição farmacêutica para o tratamento de doenças cardíacas
ME03025B (me) Postupci za povećanje efikasnosti terapije kancera usmerene na folr1
SI2582366T1 (sl) Farmacevtska kombinacija za zdravljenje bolečine
IL226359B (en) Use of t-cells for the preparation of a medicament for treatment of neurodegenerative diseases
GB201105137D0 (en) Therapeutic molecules for use in the suppression of Parkinson's disease
IL230441A0 (en) Diagnosis of Alzheimer's disease
HRP20182043T1 (hr) Upotreba anti-konfeksinskih sredstava za poboljšanje terapijskog učinka inhibitora acetilkolinesteraze
EP2611451A4 (en) DESIGN OF OLIGONUCLEOTIDE ANALOGUES AS THERAPEUTIC AGENTS
IL251543A0 (en) Use of a topical gel composition in the manufacture of a medicament for the prevention or treatment of a skin disorder
EP2704723A4 (en) TREATMENT OF POLYCYSTIC DISEASES
IL260078B (en) Therapy used to treat Gaucher disease
ES2627541T8 (es) Métodos para tratar la enfermedad de Parkinson
IL233572B (en) A pharmaceutical preparation containing a mixture with fixed doses for the treatment of Parkinson's disease
EP2914219A4 (en) SUPPORT FOR A LIMIT OF A PATIENT
DK2173366T3 (da) Anvendelse af bigift til behandling af parkinson's sygdom
EP2438076A4 (en) TARGETED MEDICAMENTAL OUTPUT IN BONES
PL3363439T3 (pl) Kompozycje terapeutyczne do leczenia cukrzycowej polineuropatii symetrycznej
FR2998801B1 (fr) Ensemble a usage medical pour l'administration d'un produit a un patient
SMT201600224B (it) Trattamento dell'osteoporosi
FR2980113B1 (fr) Balancelle d'assistance a l'effort musculaire
FR2967423B1 (fr) Ligand specifique de l'annexine 2

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed